Transaction Overview - Allscripts has reached an agreement to sell the net assets of its Hospitals & Large Physician Practices business segment to Harris Health for up to $700 million[3] - The purchase consideration includes a fixed price of $670 million paid at closing, plus contingent consideration up to $30 million based on revenue performance[3] - The after-tax proceeds from the deal are expected to be approximately $600 million[9] Business Segment Performance (Hospitals & Large Physician Practices) - The business segment's TTM revenue through 12/31/21 was $928 million, and TTM adjusted EBITDA was $145 million[7] - Management expects the business segment's revenue to be down approximately 3-4% year-over-year in 2022[7] - Management expects the business segment's adjusted EBITDA to be down approximately 10-15% year-over-year in 2022[7] - The business segment is estimated to generate approximately $50-60 million in free cash flow in 2022[7] Veradigm Business - Veradigm's overall revenue is expected to grow 6-7% in 2022[16] - Veradigm's adjusted EBITDA is expected to grow 10-15% year-over-year in 2022[17] - Free cash flow from continuing operations for Veradigm is expected to be in the range of $110 million to $120 million in 2022[17] - In 2021, Provider revenue accounted for 82% and Payer & Life Sciences revenue accounted for 18% of the total $552 million revenue[16]

Allscripts Healthcare Solutions, Inc. (OTC:MDRX) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Jenny Gelinas - Vice President, Investor Relations Paul Black - Chief Executive Officer Rick Poulton - President and Chief Financial Officer Conference Call Participants Michael Cherny - Bank of America Sean Dodge - RBC Capital Markets Charles Rhyee - Cowen and Company Jeff Garro - Piper Sandler Stephanie Demko - SVB Leerink Don Hooker - KeyBanc Operator Greetings and welcome t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 36-4392754 (State or other jurisdiction of incorporation or organizati ...

Allscripts Healthcare Solutions, Inc. (OTC:MDRX) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Jenny Gelinas - Vice President, Investor Relations Paul Black - Chief Executive Officer Rick Poulton - President & Chief Financial Officer Conference Call Participants George Hill - Deutsche Bank Sean Dodge - RBC Capital Markets Charles Rhyee - Cowen Donald Hooker - SVB Leerink Operator Good day, ladies and gentlemen, and welcome to the Allscripts' Third Quarter 2021 Earnings Co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. Washington, D.C. 20549 (Exact Name of Registrant as Specified in Its Charter) FORM 10-Q Delaware 36-4392754 (State or Other Jurisdiction of Incorporation or Organization) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 (I.R.S. Employer Identification No.) 222 Merchandise Mart, Suite 2024 Chicago, IL 60654 (Address of Principal Exec ...

Allscripts Healthcare Solutions, Inc. (OTC:MDRX) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Stephen Shulstein - Vice President, Investor Relations Paul Black - Chief Executive Officer Rick Poulton - President & Chief Financial Officer Conference Call Participants Thomas Keller - RBC Capital Markets George Hill - Deutsche Bank Eric Percher - Nephron Research Charlie Rhyee - Cowen Operator Greetings, and welcome to Allscripts' Second Quarter 2021 Earnings Call. At this tim ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 36-4392754 (State or Other Jurisdiction of Incorporation or Organi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 36-4392754 (State or Other Jurisdiction of Incorporation or Organ ...

Financial Data and Key Metrics Changes - The fourth quarter of 2020 was the best quarterly performance in years, with total non-GAAP revenue of $415 million, up from $402 million in the third quarter [31] - Adjusted EBITDA margin for the quarter was 23.4%, reflecting nearly a 1,000 basis point improvement from the first quarter of 2020 and a 700 basis point improvement year-over-year [32] - Free cash flow from continuing operations was $30 million during the fourth quarter, with operating cash flow of $56 million, excluding a $58 million payment to the DOJ [35][36] Business Line Data and Key Metrics Changes - The Veradigm business unit saw strong momentum, returning to growth with significant new bookings and larger deals, particularly in clinical research and data exchange [18] - The ambulatory enterprise added 35 new logos in the TouchWorks Professional solutions, indicating strong demand for end-to-end clinical and financial solutions [17] - The core clinical and financial solutions segment showed significant EBITDA margin expansion, although it is expected to be influenced by seasonal patterns [75] Market Data and Key Metrics Changes - The backlog increased to $4.1 billion at year-end, reflecting a considerable level of client renewals secured during the year [30] - The company noted that the US EHR market is largely a replacement market, with opportunities for growth in both domestic and international markets [66] Company Strategy and Development Direction - The company is focused on migrating clients to cloud solutions, which is expected to lower total cost of ownership and improve EHR experiences [14] - Allscripts completed the sale of EPSi and CarePort Health to unlock value from its solutions portfolio and reduce leverage [20] - The company aims to leverage its strong balance sheet and sustainable cost structure to drive long-term value creation [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to manage costs and drive year-over-year margin improvement, with a revenue outlook for 2021 set at $1.5 billion [39][40] - The management team highlighted the importance of community-based coordinated care in response to the pandemic, emphasizing the need for integrated health solutions [12][13] - The company expects to see continued growth in the Veradigm business and anticipates a stable operating environment compared to the previous year [66] Other Important Information - Allscripts was recognized as the most trusted partner in community hospitals, reflecting its commitment to client success and collaboration [22] - The company published its first corporate responsibility report, highlighting its positive impact on communities during a challenging year [24] Q&A Session Summary Question: Impact of the new Truvada Organization on Veradigm - Management does not foresee any direct impact on Veradigm's outlook from the new organization [45] Question: Migration of Sunrise to the cloud - The migration process has not been delayed by the pandemic and is expected to proceed with careful planning [46] Question: Drivers of performance in the life sciences business - The growth in Veradigm is attributed to a large market share and extensive data rights, leading to increased recognition of its value [50] Question: Adjusted EBITDA margins performance - The margin improvement was driven by a combination of better revenue mix and continued cost reductions [52] Question: Future growth opportunities - Future growth is expected from replacement market opportunities, international expansion, and new use cases in the US [66] Question: Capital deployment and share buyback - The company plans to continue share repurchases and may consider small acquisitions, depending on opportunities [60] Question: Retention performance in the core segment - Retention rates improved in 2020, with low attrition numbers indicating a positive trend for 2021 [90] Question: Feedback on Sunrise 20.0 - The response to Sunrise 20.0 has been positive, with clients eager to participate in the new features and capabilities [88]

PART I [Business](index=3&type=section&id=Item%201.%20Business) Allscripts provides healthcare IT solutions, divested CarePort and EPSi for over $1.7 billion in 2020, and maintained a $4.1 billion contract backlog - In 2020, Allscripts completed two major divestitures: selling its CarePort Health business to WellSky Corp. for **$1.35 billion** and its EPSi business to Strata Decision Technology for **$365 million**, both now reported as discontinued operations[15](index=15&type=chunk)[16](index=16&type=chunk) - The company extended its strategic alliance with Microsoft for five years, designating Microsoft as the cloud provider for its Sunrise™ EHR platform to co-develop cloud-based health IT solutions[17](index=17&type=chunk) - Allscripts operates through two primary reportable segments: Core Clinical and Financial Solutions (EHRs, financial management, managed services) and Data, Analytics and Care Coordination (payer and life sciences solutions via its Veradigm unit)[42](index=42&type=chunk)[44](index=44&type=chunk) Contract Backlog as of December 31, 2020 | Metric | Value | Note | | :--- | :--- | :--- | | **Total Contract Backlog** | $4.1 billion | Represents the value of executed contracts not yet recognized as revenue | | **Revenue Recognition in 2021** | ~35% | Estimated portion of the backlog to be recognized as revenue in the upcoming year | - As of December 31, 2020, the company had approximately **8,400 employees**, with the majority located in the United States (**58.9%**) and India (**36.4%**)[54](index=54&type=chunk) [Risk Factors](index=14&type=section&id=Item%201A.%20Risk%20Factors) The company identifies significant risks including the COVID-19 pandemic's impact, intense industry competition, complex regulatory environment, potential product failures, security breaches, client reliance, and the Practice Fusion DOJ settlement - The COVID-19 pandemic has negatively impacted revenue by causing delays in software deals and professional services implementations, and by reducing patient volumes for its clients[70](index=70&type=chunk) - The company operates in a highly competitive market and faces pressure from industry consolidation, which may decrease the number of potential clients and increase pricing pressure[73](index=73&type=chunk)[76](index=76&type=chunk) - Significant risk is associated with the failure of its subsidiary, Practice Fusion, to comply with the terms of its settlement agreements with the U.S. Department of Justice (DOJ), which involved a criminal fine of **$25.3 million**, a forfeiture of **$959,700**, and a civil settlement of **$118.6 million**[101](index=101&type=chunk)[103](index=103&type=chunk)[104](index=104&type=chunk) - The business model depends on maintaining relationships with existing clients, with one client accounting for **12% of revenue** for the year ended December 31, 2020[93](index=93&type=chunk) - The company is exposed to information security risks, including a ransomware attack in 2018 that impacted two data centers and a more recent incident involving unauthorized access to personally identifiable information[97](index=97&type=chunk) - The company's debt agreements contain restrictive covenants and require it to maintain specified financial ratios, a breach of which could result in an event of default and acceleration of debt[161](index=161&type=chunk) [Unresolved Staff Comments](index=32&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports no unresolved staff comments from the U.S. Securities and Exchange Commission - None[177](index=177&type=chunk) [Properties](index=33&type=section&id=Item%202.%20Properties) Allscripts' corporate headquarters is in Chicago, Illinois, leasing approximately 1.1 million square feet of office space globally as of December 31, 2020 - As of December 31, 2020, the company leased **1.1 million square feet** of building space worldwide[178](index=178&type=chunk) [Legal Proceedings](index=33&type=section&id=Item%203.%20Legal%20Proceedings) Information regarding legal proceedings is incorporated by reference from Note 22, "Contingencies," in the consolidated financial statements - Refer to Note 22, "Contingencies," to our consolidated financial statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K[179](index=179&type=chunk) [Mine Safety Disclosures](index=33&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's business - Not applicable[180](index=180&type=chunk) PART II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=34&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) Allscripts' common stock trades on Nasdaq under "MDRX"; the Board approved a new $300 million stock repurchase program in November 2020, leading to 18.2 million shares repurchased in Q4, with no current intent to pay cash dividends - On November 18, 2020, the Board approved a new stock purchase program authorizing the repurchase of up to **$300 million** of common stock through December 31, 2021, replacing the 2018 program[184](index=184&type=chunk) - In November 2020, the company entered into Accelerated Share Repurchase (ASR) agreements for a total of **$200 million**, receiving an initial delivery of **11.7 million shares** in December 2020[185](index=185&type=chunk) Share Repurchases in Q4 2020 | Period | Total Shares Purchased (thousands) | Average Price Paid Per Share | | :--- | :--- | :--- | | Oct 2020 | 0 | $0.00 | | Nov 2020 | 6,535 | $12.16 | | Dec 2020 | 11,696 | N/A | | **Total Q4** | **18,231** | **$12.16** | - The company currently does not intend to declare or pay cash dividends on its common stock[191](index=191&type=chunk) [Selected Financial Data](index=37&type=section&id=Item%206.%20Selected%20Financial%20Data) This section presents a five-year summary of key consolidated financial data, showing 2020 revenue of $1.50 billion, a net income of $700.4 million primarily from discontinued operations, and reduced long-term debt Selected Consolidated Statements of Operations Data (2018-2020) | (In thousands) | 2020 | 2019 | 2018 | | :--- | :--- | :--- | :--- | | **Revenue** | $1,502,700 | $1,632,611 | $1,617,841 | | **Gross profit** | $565,695 | $610,287 | $621,391 | | **Loss from operations** | $(130,880) | $(99,689) | $(168,384) | | **Income from discontinued operations, net of tax** | $833,026 | $55,809 | $451,023 | | **Net income (loss)** | $700,407 | $(182,602) | $407,807 | | **Diluted EPS (Continuing ops)** | $(0.83) | $(1.43) | $(0.22) | | **Diluted EPS (Discontinued ops)** | $5.23 | $0.33 | $2.29 | Selected Consolidated Balance Sheet Data (as of Dec 31) | (In thousands) | 2020 | 2019 | 2018 | | :--- | :--- | :--- | :--- | | **Cash, cash equivalents and marketable securities** | $537,465 | $137,539 | $184,795 | | **Total assets** | $2,917,618 | $3,205,739 | $3,181,484 | | **Long-term debt** | $167,587 | $551,004 | $647,539 | | **Total stockholders' equity** | $1,666,243 | $1,285,188 | $1,580,427 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=40&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses 2020 financial performance, highlighting an 8% revenue decline due to COVID-19, a significant net income boost from divestitures, and a strong liquidity position with $538 million cash and a stable $4.1 billion contract backlog [Results of Operations](index=48&type=section&id=Results%20of%20Operations) Total revenue decreased 8.0% to $1.50 billion in 2020 due to lower non-recurring revenue, while gross margin slightly improved, and a significant $833.0 million income from discontinued operations offset a loss from continuing operations Revenue Breakdown (2019 vs 2020) | Revenue Type | 2020 (in thousands) | 2019 (in thousands) | % Change | | :--- | :--- | :--- | :--- | | Recurring revenue | $1,222,731 | $1,278,456 | (4.4%) | | Non-recurring revenue | $279,969 | $354,155 | (20.9%) | | **Total revenue** | **$1,502,700** | **$1,632,611** | **(8.0%)** | Gross Profit and Margin (2019 vs 2020) | Metric | 2020 | 2019 | | :--- | :--- | :--- | | **Gross Profit** | $565.7 M | $610.3 M | | **Gross Margin %** | 37.6% | 37.4% | - Asset impairment charges increased significantly to **$75.0 million** in 2020 from **$10.8 million** in 2019, primarily related to write-offs of a customer relationship intangible asset (**$23.1 million**), capitalized software (**$31.2 million**), and deferred private cloud hosting costs (**$34.3 million**)[274](index=274&type=chunk) - Income from discontinued operations was **$833.0 million** in 2020, including a **$1.157 billion** pre-tax gain on the sale of the CarePort and EPSi businesses[292](index=292&type=chunk) [Segment Operations](index=55&type=section&id=Segment%20Operations) In 2020, Core Clinical and Financial Solutions revenue decreased by 8.9% to $1.25 billion, increasing its operating loss, while Data, Analytics and Care Coordination revenue was flat, with an improved operating loss Core Clinical and Financial Solutions Performance (2019 vs 2020) | Metric (in thousands) | 2020 | 2019 | % Change | | :--- | :--- | :--- | :--- | | **Revenue** | $1,254,249 | $1,377,147 | (8.9%) | | **Gross Profit** | $434,288 | $473,033 | (8.2%) | | **Loss from Operations** | $(116,139) | $(80,465) | 44.3% | Data, Analytics and Care Coordination Performance (2019 vs 2020) | Metric (in thousands) | 2020 | 2019 | % Change | | :--- | :--- | :--- | :--- | | **Revenue** | $261,321 | $262,664 | (0.5%) | | **Gross Profit** | $131,407 | $137,254 | (4.3%) | | **Loss from Operations** | $(14,741) | $(19,224) | (23.3%) | [Liquidity and Capital Resources](index=57&type=section&id=Liquidity%20and%20Capital%20Resources) As of December 31, 2020, Allscripts had strong liquidity with $538 million cash and $899 million available credit, with operating cash flow impacted by a $147 million DOJ settlement payment, and investing activities boosted by $1.71 billion from divestitures - As of December 31, 2020, principal sources of liquidity consisted of **$538 million** in cash and cash equivalents and **$899 million** of available borrowing capacity under the Revolving Facility[316](index=316&type=chunk) Cash Flow Summary (2019 vs 2020) | (In thousands) | 2020 | 2019 | | :--- | :--- | :--- | | **Net cash (used in) provided by operating activities** | $(106,715) | $46,254 | | **Net cash provided by (used in) investing activities** | $1,615,188 | $(161,056) | | **Net cash (used in) provided by financing activities** | $(1,109,759) | $67,343 | - Operating cash flow in 2020 was negatively impacted by **$147 million** in payments related to the DOJ settlement for the Practice Fusion investigation[318](index=318&type=chunk) - Investing cash flow was primarily driven by **$1.71 billion** in cash received from the sales of the CarePort and EPSi businesses[322](index=322&type=chunk)[323](index=323&type=chunk) - Financing activities included significant debt repayments and share repurchases, including a **$200 million** accelerated share repurchase program[327](index=327&type=chunk)[328](index=328&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=62&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks are interest rate and foreign currency fluctuations, with minimal interest rate risk in 2020 and foreign currency risk mitigated by hedging Indian Rupee expenses - Interest rate risk was minimal as of year-end 2020, with no debt outstanding under the Senior Secured Credit Facility[343](index=343&type=chunk) - The company is exposed to foreign currency risk, particularly with the Indian Rupee (INR), and utilizes forward contracts to hedge a portion of forecasted INR-denominated expenses[344](index=344&type=chunk) [Financial Statements and Supplementary Data](index=63&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section includes audited consolidated financial statements for 2020, an unqualified auditor's opinion from Grant Thornton LLP, and details the significant impact of CarePort and EPSi divestitures presented as discontinued operations - The independent auditor, Grant Thornton LLP, issued an unqualified opinion on the financial statements and internal control over financial reporting[348](index=348&type=chunk)[360](index=360&type=chunk) - The auditor identified "Revenue Recognition - Determination of distinct performance obligations and application of stand-alone selling prices" as a critical audit matter due to the complexity and judgment required[354](index=354&type=chunk)[356](index=356&type=chunk) [Note 2. Revenue from Contracts with Customers](index=77&type=section&id=Note%202.%20Revenue%20from%20Contracts%20with%20Customers) Revenue is disaggregated into software delivery, support, maintenance, and client services, with a total contract backlog of $4.1 billion as of December 31, 2020, with 35% expected in 2021 Disaggregation of Revenue by Type | (In thousands) | 2020 | 2019 | 2018 | | :--- | :--- | :--- | :--- | | **Recurring revenue** | $1,222,731 | $1,278,456 | $1,313,281 | | **Non-recurring revenue** | $279,969 | $354,155 | $304,560 | | **Total revenue** | **$1,502,700** | **$1,632,611** | **$1,617,841** | - The total contract backlog as of December 31, 2020, was **$4.1 billion**, with approximately **35%** expected to be recognized as revenue over the next 12 months[427](index=427&type=chunk) [Note 5. Business Combinations and Divestitures](index=84&type=section&id=Note%205.%20Business%20Combinations%20and%20Divestitures) In 2020, Allscripts completed the sales of CarePort for $1.35 billion (pre-tax gain $933.9 million) and EPSi for $365.0 million (pre-tax gain $222.6 million), both treated as discontinued operations - Completed the sale of the CarePort business on December 31, 2020, for **$1.35 billion**, resulting in a pre-tax gain of **$933.9 million**[459](index=459&type=chunk) - Completed the sale of the EPSi business on October 15, 2020, for **$365.0 million**, resulting in a pre-tax gain of **$222.6 million**[460](index=460&type=chunk) [Note 8. Goodwill and Intangible Assets](index=90&type=section&id=Note%208.%20Goodwill%20and%20Intangible%20Assets) As of December 31, 2020, the company had $974.7 million in goodwill and $286.6 million in net intangible assets, with no goodwill impairment in 2020, contrasting with a $25.7 million charge in 2019 Goodwill and Intangible Assets (Net) | (In thousands) | Dec 31, 2020 | Dec 31, 2019 | | :--- | :--- | :--- | | **Goodwill** | $974,729 | $974,110 | | **Intangible Assets, Net** | $286,602 | $367,128 | - The annual goodwill impairment test as of October 1, 2020, resulted in no impairment charges[489](index=489&type=chunk) - In 2019, a goodwill impairment charge of **$25.7 million** was recognized related to the Hospitals and Health Systems (HHS) reporting unit[490](index=490&type=chunk) [Note 10. Debt](index=93&type=section&id=Note%2010.%20Debt) As of December 31, 2020, total net debt significantly reduced to $167.6 million from $915.5 million in 2019, primarily due to repayments of the Senior Secured Credit Facility and 1.25% Notes, with no outstanding borrowings on the Revolving Facility Debt Outstanding (Net Carrying Amount) | (In thousands) | Dec 31, 2020 | Dec 31, 2019 | | :--- | :--- | :--- | | 0.875% Convertible Senior Notes | $167,587 | $173,245 | | 1.25% Cash Convertible Senior Notes | $0 | $337,448 | | Senior Secured Credit Facility | $0 | $404,776 | | **Total Long-Term Debt** | **$167,587** | **$551,004** | - The **1.25% Notes** with a principal of **$345.0 million** matured and were paid in full on July 1, 2020[388](index=388&type=chunk)[529](index=529&type=chunk) - As of December 31, 2020, there were no amounts outstanding under the Term Loan or the **$900 million** Revolving Facility, with **$898.9 million** of available borrowing capacity[523](index=523&type=chunk)[525](index=525&type=chunk) [Note 22. Contingencies](index=117&type=section&id=Note%2022.%20Contingencies) This note details legal matters including an EIS business civil investigative demand indemnified by McKesson and the Practice Fusion DOJ settlement for approximately $145 million, which has been fully paid - The acquired EIS Business is subject to a civil investigative demand related to EHR certification, for which Allscripts is indemnified by the seller, McKesson[617](index=617&type=chunk) - On January 27, 2020, the Practice Fusion subsidiary entered into settlement agreements with the DOJ, resolving investigations into violations of the Anti-Kickback Statute and False Claims Act, requiring payments of a **$25.3 million** criminal fine, a **$0.96 million** forfeiture, and a **$118.6 million** civil settlement, all of which have been paid[618](index=618&type=chunk) [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=120&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) The company reports no changes in or disagreements with its accountants on accounting and financial disclosure - None[623](index=623&type=chunk) [Controls and Procedures](index=120&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures and internal control over financial reporting were effective as of December 31, 2020, a conclusion audited by Grant Thornton LLP - Management concluded that the company's disclosure controls and procedures were effective as of December 31, 2020[625](index=625&type=chunk) - Management concluded that internal control over financial reporting was effective as of December 31, 2020, which was audited by Grant Thornton LLP[627](index=627&type=chunk) PART III [Directors, Executive Officers and Corporate Governance](index=121&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) Information on directors, executive officers, and corporate governance is incorporated by reference from the company's 2021 Proxy Statement - Information required by this item is incorporated by reference from the registrant's definitive proxy statement for its 2021 annual meeting of stockholders[631](index=631&type=chunk) [Executive Compensation](index=121&type=section&id=Item%2011.%20Executive%20Compensation) Information on executive compensation, including the Compensation Discussion and Analysis, is incorporated by reference from the company's 2021 Proxy Statement - Information required by this item is incorporated by reference from the registrant's definitive proxy statement for its 2021 annual meeting of stockholders[632](index=632&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=121&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Information on security ownership of beneficial owners, management, and equity compensation plans is incorporated by reference from the company's 2021 Proxy Statement - Information required by this item is incorporated by reference from the registrant's definitive proxy statement for its 2021 annual meeting of stockholders[633](index=633&type=chunk) [Certain Relationships and Related Transactions, and Director Independence](index=121&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information on related party transactions and director independence is incorporated by reference from the company's 2021 Proxy Statement - Information required by this item is incorporated by reference from the registrant's definitive proxy statement for its 2021 annual meeting of stockholders[634](index=634&type=chunk) [Principal Accountant Fees and Services](index=121&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) Information on fees paid to the principal accountant and audit committee pre-approval policies is incorporated by reference from the company's 2021 Proxy Statement - Information required by this item is incorporated by reference from the registrant's definitive proxy statement for its 2021 annual meeting of stockholders[635](index=635&type=chunk) PART IV [Exhibits and Financial Statement Schedules](index=122&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section lists the financial statements, financial statement schedules, and exhibits filed as part of the Annual Report on Form 10-K - This section contains the list of financial statements, financial statement schedules (Schedule II—Valuation and Qualifying Accounts), and all exhibits filed with the Form 10-K[637](index=637&type=chunk)[638](index=638&type=chunk)[641](index=641&type=chunk) [Form 10-K Summary](index=127&type=section&id=Item%2016.%20Form%2010-K%20Summary) The company indicates that no Form 10-K summary is provided - None[646](index=646&type=chunk)